A 29-year-old male patient presented to one of our small rural hospitals with a history of seizures and falls. He has a history of poor compliance with his prescribed antiepileptic medications, including phenytoin and carbamazepine. During the short stay, he had three seizures and was commenced on loading doses of levetiracetam, and subsequently continued doses of levetiracetam and valproate. It was noted he had a middle cerebral artery stroke with an embolus at the origin of the left carotid along with extensive cerebral oedema. He had developed hemiplegia and dysarthria. He was then transferred to our tertiary-level hospital. He underwent hemicraniectomy and was put on dalteparin. Thirty-three days post commencement on valproate, a request was received for valproate estimation to monitor the appropriateness of the dosage. The serum sample was analysed on a Beckman DxC800 general chemistry analyser (Beckman Coulter, Brea, CA, USA) by a particle-enhanced turbidimetric inhibition immunoassay method which uses a mouse monoclonal antibody. From the long-term quality control data, the method has a coefficient of variation (CV) of 5.6% at a level of 31.4 mg/L and 4.0% at a level of 136 mg/L. The result was suppressed with a high absorbance flag ("ABS HI"), indicating the absorbance change during the measuring period was outside acceptable limits in order to obtain a meaningful result. The sample was diluted 1:2 with normal saline and the outcome was the same. The sample was further diluted 1:3 and the result was <0.1 mg/L. The sample was then diluted 1:2 and 1:3 with another patient's serum with a normal chemistry profile and free of valproate. The results were identical to what was observed with the saline dilution, 1:2 with high absorbance flag and for 1:3 <0.1 mg/L. The sample was then sent for analysis to another laboratory on a Vitros analyser (Ortho-Clinical Diagnostics Rochester, NY, USA), using a competitive immunoassay. The result was 28 mg/L (40-100). No further testing could be conducted due to shortage of serum sample.
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The Beckman method insert does not indicate any known interferences. The only interference publication was from the presence of paraprotein [1] , and ethanol was a suitable precipitant to obtain accurate results.
Twelve days later, a sample was collected for followup monitoring of the valproate, and again, no result could be obtained on the Beckman analyser, and the same high absorbance error flag occurred. An aliquot was sent for analysis on the Vitros method and the result was 84 mg/L. The total protein was 65 g/L (60-80), albumin 34 g/L (35-50) and globulins 31 g/L (25-45). Considerations were given as to the causative problem, including the presence of heterophile antibodies, a paraprotein or interference from a cross reacting drug. PEG extraction was performed and the result was <0.1 mg/L, with the same high absorbance flag. PEG extraction was shown not to be effective in providing appropriate recovery in the presence of a paraprotein [1] . However, PEG treatment has been successful in providing accurate digoxin results in patients treated with DigiFab [2] .
To test for potential heterophile antibody presence, the serum was treated in a Heterophile Blocking Tube (Scantibodies Laboratory, #3IX762, Santee, CA, USA) to potentially remove mouse heterophile antibodies. Heparin from lithium heparin plasma has been associated with increasing turbidity and interference in glucose and GGT [3] ; thus, dalteparin was considered, as it may contribute in a similar manner. However, no further testing was performed as the samples were serum.
A 500-mg levetiracetam tablet (Keppra, UCB Pharma SA, Belgium) was obtained and this was dissolved in 7 mL of normal saline. This, along with 1:10 and 1:100 saline dilutions, was analysed for valproate, and there were no cross reactivities; all three results were <0.1 mg/L.
If protein (heterophile, paraprotein, etc.) was the causative agent, in order not to minimize variation in the serum, the next experiment we conducted was to boil the serum, denature the proteins and release the valproate. A 1-mL aliquot was transferred to a microtube, sealed and placed in a container with boiling water for 1 min, allowing the serum to precipitate and gelatinise. The sample was allowed to cool down, and then centrifuged in a Biofuge Primo centrifuge for 10 min at 15,000 g (Heraeus, Osterode, Germany). The clear supernatant was aspirated, then dispensed into an aliquot tube and analysed for valproate. The result was 86 mg/L, which was almost identical to the Vitros result, 84 mg/L. To validate if the boiling method was suitable, two internal quality controls (concentrations 30 and 127 mg/L) along with seven patient serum samples covering the widest possible concentration range (1.7-100 mg/L) were boiled and the supernatants analysed. The mean difference was 0.9% and the range of difference was -12.7% to 12.6%, t-test p-value = 0.2317. The statistical analysis was performed using Analyse-It software (Analyse-It, Leeds, UK). The results are presented in Figure 1 . Parts A, B and C clearly show the absorbance error while part D from the supernatent post boiling clearly shows it has normal absorbance characteristics like a normal patient, part E. The Passing Bablok, part F, plot demonstrated the boiling process provides suitable recoveries for the process to be implemented to derive accurate results for the patient samples.
The easiest way to boil the samples was to boil water in a suitable container in a microwave then place the serum samples without being submerged and time the boiling process for a minute. The major limitation was the gelatinised serum can be difficult to centrifuge and release the supernatant. Simply crushing or jabbing the gelatinised serum while in the microtube with a plastic pipette into smaller pieces allowed for easier and greater volume release of the supernatant.
As Dasgupta points out, immunoassays can be effected by both endogenous and exogenous compounds including metabolites of the parent drug, which can lead to difficulties in obtaining an accurate result [4] .
In summary, the causative agent has been removed by the boiling process. It could well be a interference from a heterophile antibody, another protein that precipitates, or some form of cross reactivity that we have not considered or tested for.
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